Related Experiment Video

Updated: Apr 20, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K

Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left

Jeong Hoon Yang1, Joo-Yong Hahn2, Young Bin Song3

  • 1Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

BMJ (Clinical Research Ed.)
|November 16, 2014
PubMed

Insights

Angiotensin receptor blockers are as effective as ACE inhibitors for treating ST-elevation myocardial infarction patients with preserved heart function. These blockers offer a comparable alternative to ACE inhibitors, improving cardiac outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • ST-segment elevation myocardial infarction (STEMI) management focuses on preserving left ventricular systolic function.
  • Renin-angiotensin system (RAS) blockers, including angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors, are crucial in post-MI care.

Purpose of the Study:

  • To evaluate the association between ARB treatment and clinical outcomes in STEMI patients with preserved left ventricular systolic function (LVEF ≥ 40%).
  • To compare the efficacy of ARBs versus ACE inhibitors and no RAS blockade in this patient cohort.

Main Methods:

  • Prospective cohort study utilizing a nationwide Korean registry (November 2005 - September 2010).
  • Included 6698 STEMI patients who underwent primary percutaneous coronary intervention with LVEF ≥ 40%.
  • Compared outcomes (cardiac death or myocardial infarction) among ARB, ACE inhibitor, and no RAS blocker groups, with propensity score matching.

Main Results:

  • After propensity score matching, ARB use showed no significant difference in cardiac death or myocardial infarction compared to ACE inhibitor use (1.8% vs. 2.0%, aHR 0.65).
  • ARB use was associated with a significantly lower rate of cardiac death or myocardial infarction compared to no RAS blocker use (1.7% vs. 3.1%, aHR 0.35).

Conclusions:

  • Angiotensin receptor blockers demonstrate comparable efficacy to ACE inhibitors in STEMI patients with preserved left ventricular systolic function.
  • ARBs represent a viable alternative to ACE inhibitors for this specific patient population, offering similar cardioprotective benefits.
Abstract

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
594
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
562
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K